Business Context and Reporting Period
This Form 8-K is a current report filed by Ocular Therapeutix, Inc. on September 29, 2022. The filing serves as a Regulation FD disclosure regarding the presentation of clinical data and slides at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory disclosure of non-financial clinical events.
Material Changes
There are no material financial changes reported in this document. The material event is the public disclosure of clinical trial information:
- Slides presented by Peter K. Kaiser, M.D., Chief Medical Advisor, Retina, at the Eyecelerator @ AAO 2022 Retina Showcase on September 29, 2022.
- Planned posting of slides regarding interim data from the U.S. Phase 1 clinical trial evaluating OTX-TKI, to be presented by Dilsher Dhoot, M.D., on September 30, 2022.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors. The primary focus is the dissemination of interim clinical data for the OTX-TKI candidate.
Investor Verification Checklist
- Verify the content of the slides posted on the company's Investor Relations website regarding the OTX-TKI Phase 1 trial.
- Confirm the date and details of the presentation by Dilsher Dhoot, M.D., at the Retina Subspecialty Day on September 30, 2022.
- Review the company's website for the full text of the interim data to assess clinical progress.